"While the restructuring impacts valued colleagues, it is a natural consequence of our strategic shift announced in February and necessary to position Integrum for long-term success. By focusing our organization on commercialization activities, we can better serve our customers and accelerate the uptake of OPRA Implant System in the US and selected European markets. We are grateful for the contributions of all our team members and are committed to supporting those affected through this transition," said Martin Hillsten, CEO of Integrum.

Following the completion of this restructuring, Integrum's organization will be optimized to:

• Accelerate product commercialization with enhanced focus on targeted top-tier orthopaedic treatment centers, Centers of Excellence, and efforts to further exploit commercial opportunities in the aftermarket.
• Streamline operations to improve efficiency and reduce overhead costs.
• Direct R&D efforts toward the top-priority, most commercially promising development projects.

In February 2025, Integrum announced a cost reduction program expected to result in SEK 20 million in annual cost savings when fully implemented at the beginning of 2026. The current restructuring, together with new measures to reduce R&D activities and consultancy costs, is expected to further reduce the company's cost base.